HDR-brachytherapy in the management of skin, oral mucosa, rectal cancer and squamous cell carcinoma of the anus: clinical outcomes

79 patients treated with an applicative or intracavitary (192) Ir HDR-BT on the GammaMed Plus from 2014 to 2017. The treatment management depended on the stage of the tumour. As the definitive course, brachytherapy was used for Tis-T1N0M0 and recurrent tumours. For T2N0M0 HDR-BT was applied with external beam radiation therapy (EBRT) or as the postoperative treatment. Short-term treatment results allow us to consider the used programs as effective and safe treatment method. The clinical complete response rate after RT completion was 100%. We have seen acute toxicity only Grade 1-2. However, it needs observed a long-term follow-up. We confirm the excellent results with RT in T1 and T2 lesions of skin, oral mucosa, rectal cancer and squamous cell carcinoma of the anus. Applicative and intracavitary HDR-brachytherapy is effective method of radiotherapy and it may use as the definitive (alone or in combination with EBRT) and postoperative management.